Cencora, Inc.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cencora, Inc. and other ETFs, options, and stocks.

About COR

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. 

CEO
Robert P. Mauch
CEORobert P. Mauch
Employees
51,000
Employees51,000
Headquarters
Conshohocken, Pennsylvania
HeadquartersConshohocken, Pennsylvania
Founded
1947
Founded1947
Employees
51,000
Employees51,000

COR Key Statistics

Market cap
71.04B
Market cap71.04B
Price-Earnings ratio
45.67
Price-Earnings ratio45.67
Dividend yield
0.62%
Dividend yield0.62%
Average volume
1.16M
Average volume1.16M
High today
$366.15
High today$366.15
Low today
$361.81
Low today$361.81
Open price
$363.10
Open price$363.10
Volume
479.89K
Volume479.89K
52 Week high
$377.54
52 Week high$377.54
52 Week low
$237.71
52 Week low$237.71

Stock Snapshot

The current Cencora, Inc.(COR) stock price is $365.20, with a market capitalization of 71.04B. The stock trades at a price-to-earnings (P/E) ratio of 45.67 and offers a dividend yield of 61.9%.

During the trading session on 2026-02-03, Cencora, Inc.(COR) shares reached a daily high of $366.15 and a low of $361.81. At a current price of $365.20, the stock is +0.9% higher than the low and still -0.3% under the high.

Trading activity shows a volume of 479.89K, compared to an average daily volume of 1.16M.

The stock's 52-week range extends from a low of $237.71 to a high of $377.54.

The stock's 52-week range extends from a low of $237.71 to a high of $377.54.

COR News

Simply Wall St 4d
Is Cencora’s Rare-Disease Commercialization Push With Curant Reshaping Its Investment Narrative?

In January 2026, Curant Health's Curant Rare announced a collaboration with Cencora to offer an integrated commercialization solution for rare disease therapies...

Is Cencora’s Rare-Disease Commercialization Push With Curant Reshaping Its Investment Narrative?
TipRanks 5d
Morgan Stanley upgrades Cencora to Overweight on specialty position

Morgan Stanley upgraded Cencora (COR) to Overweight from Equal Weight with a price target of $400, up from $361. The firm says the company has positioned itself...

TipRanks 5d
Cencora upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Cencora (COR) to Overweight from Equal Weight with a $400 price target Published first on TheFly – the ultimate source for real-time, m...

Analyst ratings

80%

of 20 ratings
Buy
80%
Hold
15%
Sell
5%

People also own

Based on the portfolios of people who own COR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.